Your browser doesn't support javascript.
loading
Demonstrating laboratory proficiency in bacterial mutagenicity assays for regulatory submission.
Levy, Dan D; Hakura, Atsushi; Elespuru, Rosalie K; Escobar, Patricia A; Kato, Masayuki; Lott, Jasmin; Moore, Martha M; Sugiyama, Kei-Ichi.
Afiliação
  • Levy DD; US Food and Drug Administration Center for Food Safety and Applied Nutrition, College Park, MD, USA. Electronic address: Dan.levy@fda.hhs.gov.
  • Hakura A; Tsukuba Drug Safety, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan.
  • Elespuru RK; US Food and Drug Administration Center for Devices and Radiological Health, Silver Spring, MD, USA.
  • Escobar PA; Merck Research Laboratories, Merck & Co, West Point, PA, USA.
  • Kato M; CMIC Pharma Science Co., Ltd., Hokuto, Yamanashi, Japan.
  • Lott J; Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
  • Moore MM; Ramboll US Corporation, Little Rock, AR, USA.
  • Sugiyama KI; Division of Genetics and Mutagenesis, National Institute of Health Sciences, Kawasaki, Kanagawa, Japan.
Article em En | MEDLINE | ID: mdl-31708077
ABSTRACT
The bacterial reverse mutation test is a mainstay for evaluation of mutagenicity predicting the carcinogenic potential of a test substance and is recommended by regulatory agencies across the globe. The popularity of the test is due, in part, to the relatively low cost, rapid results and small amount of test material required compared to most other toxicological tests as well as the near universal acceptance of the toxicological significance of a clear positive or negative result. Most laboratories follow the Organization for Economic Cooperation and Development Test Guideline 471 (TG471) or national guidelines based on TG471. Regulatory agencies in most countries are obligated to consider results from tests which meet the recommendations laid out in TG471. Nonetheless, laboratories unfamiliar with the test sometimes have trouble generating reliable, reproducible results. TG471 is a test guideline, not a detailed test protocol. A group of experts from regulatory agencies and laboratories which use the assay has assembled here a set of recommendations which if followed, will allow an inexperienced laboratory to acquire proficiency in assay conduct. These include recommendations for how to create a cell bank for the 5 Salmonella typhimurium/Escherichia coli strains and develop a laboratory protocol to reliably culture each strain to ensure each culture has the characteristics which allow adequate sensitivity for detection of mutagens using the test as described in TG471. By testing compounds on the provided lists of positive and negative test substances, the laboratory will have surmounted many of the problems commonly encountered during routine testing of unknown chemicals and will have gained the experience necessary to prepare the detailed protocol needed for performing the test under Good Laboratory Procedures and the laboratory will have generated the historical positive and negative control databases which are needed for test reports which adhere to TG471.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Salmonella typhimurium / Eficiência Organizacional / Escherichia coli / Laboratórios / Testes de Mutagenicidade Tipo de estudo: Prognostic_studies Idioma: En Revista: Mutat Res Genet Toxicol Environ Mutagen Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Salmonella typhimurium / Eficiência Organizacional / Escherichia coli / Laboratórios / Testes de Mutagenicidade Tipo de estudo: Prognostic_studies Idioma: En Revista: Mutat Res Genet Toxicol Environ Mutagen Ano de publicação: 2019 Tipo de documento: Article